Nader Hirmas, Rainer Hamacher, Miriam Sraieb, Lukas Kessler, Kim M Pabst, Francesco Barbato, Helena Lanzafame, Stefan Kasper, Michael Nader, Claudia Kesch, Bastian von Tresckow, Hubertus Hautzel, Clemens Aigner, Martin Glas, Martin Stuschke, Sherko Kümmel, Philipp Harter, Celine Lugnier, Waldemar Uhl, Boris Hadaschik, Viktor Grünwald, Jens T Siveke, Ken Herrmann, Wolfgang P Fendler
To assess the diagnostic accuracy of 68 Ga-labeled fibroblast activation protein inhibitor (FAPI) and 18 F-labeled FDG PET for the detection of various tumors, we performed a head-to-head comparison of both imaging modalities across a range of tumor entities as part of our ongoing 68 Ga-FAPI PET observational trial. Methods: The study included 115 patients with 8 tumor entities who received imaging with 68 Ga-FAPI for tumor staging or restaging between October 2018 and March 2022. Of those, 103 patients received concomitant imaging with 68 Ga-FAPI and 18 F-FDG PET and had adequate lesion validation for accuracy analysis...
February 8, 2024: Journal of Nuclear Medicine